Drug candidate eCD4-Ig demonstrates durable protection against HIV infection
A drug candidate known as “eCD4-Ig” — a fusion of CD4-Ig with a small CCR5-mimetic sulfopeptide — has efficiently neutralised 100% of a diverse panel of HIV-1, HIV-2 and simian immunodeficiency virus isolates.…